1. Willemze R, Jaffe ES, Burg G, Cerroni L, Berti E, Swerdlow SH, et al. WHO-EORTC classification for cutaneous lymphomas. Blood. 2005; 105:3768–3785.
Article
2. Souissi A, Ben Lagha I, Jendoubi F, Drissi H, Chelly I, Mokni M. Spiky follicular mycosis fungoides: a trichoscopic feature. J Eur Acad Dermatol Venereol. 2019; 33:e252–e253.
Article
3. Rodney IJ, Kindred C, Angra K, Qutub ON, Villanueva AR, Halder RM. Hypopigmented mycosis fungoides: a retrospective clinicohistopathologic study. J Eur Acad Dermatol Venereol. 2017; 31:808–814.
Article
4. Pankratov O, Gradova S, Tarasevich S, Pankratov V. Poikilodermatous mycosis fungoides: clinical and histopathological analysis of a case and literature review. Acta Dermatovenerol Alp Pannonica Adriat. 2015; 24:37–41.
Article
5. Willemze R, Cerroni L, Kempf W, Berti E, Facchetti F, Swerdlow SH, et al. The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas. Blood. 2019; 133:1703–1714.
Article
6. Ku LS, Lo KK. Mycosis fungoides--a retrospective study of 40 cases in Hong Kong. Int J Dermatol. 2005; 44:215–220.
7. Ishiji T, Takagi Y, Niimura M. Cutaneous lymphomas in Tokyo: analysis of 62 cases in a dermatology clinic. Int J Dermatol. 2001; 40:37–40.
Article
8. Liu J, Yu X, Liu Y, Jin H, Ma D, Qu T, et al. Relative frequency and survival of primary cutaneous lymphomas: a retrospective analysis of 98 patients. Chin Med J (Engl). 2014; 127:645–650.
9. Tan EST, Tang MBY, Tan SH. Retrospective 5XMLLink_XYZyear review of 131 patients with mycosis fungoides and Sézary syndrome seen at the National Skin Centre, Singapore. Australas J Dermatol. 2006; 47:248–252.
Article
10. Su C, Nguyen KA, Bai HX, Cao Y, Tao Y, Xiao R, et al. Racial disparity in mycosis fungoides: an analysis of 4495 cases from the US National Cancer Database. J Am Acad Dermatol. 2017; 77:497–502.e2.
Article
11. Eder J, Kern A, Moser J, Kitzwögerer M, Sedivy R, Trautinger F. Frequency of primary cutaneous lymphoma variants in Austria: retrospective data from a dermatology referral centre between 2006 and 2013. J Eur Acad Dermatol Venereol. 2015; 29:1517–1523.
Article
12. Bradford PT, Devesa SS, Anderson WF, Toro JR. Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases. Blood. 2009; 113:5064–5073.
Article
13. Agar NS, Wedgeworth E, Crichton S, Mitchell TJ, Cox M, Ferreira S, et al. Survival outcomes and prognostic factors in mycosis fungoides/Sézary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal. J Clin Oncol. 2010; 28:4730–4739.
Article
14. Lebowitz E, Geller S, Flores E, Pulitzer M, Horwitz S, Moskowitz A, et al. Survival, disease progression and prognostic factors in elderly patients with mycosis fungoides and Sézary syndrome: a retrospective analysis of 174 patients. J Eur Acad Dermatol Venereol. 2019; 33:108–114.
Article
15. Olsen EA, Hodak E, Anderson T, Carter JB, Henderson M, Cooper K, et al. Guidelines for phototherapy of mycosis fungoides and Sézary syndrome: a consensus statement of the United States Cutaneous Lymphoma Consortium. J Am Acad Dermatol. 2016; 74:27–58.
Article
16. Stadler R, Otto HG, Luger T, Henz BM, Kuhl P, Zwingers T, et al. Prosepctive randomized multicenter clinical traial on the use of interferon-2α plus acitretin Photo(chemo)therapie April 2007 24 versus interferon - 2α plus PUVA in patients with cutaneous T-cell lymphoma stages I and II. Blood. 1998; 92:3578–3581.
17. Olisova OY, Megna M, Grekova EV, Zaslavsky DV, Gorenkova LG, Sidikov AA, et al. PUVA and interferon α2b combined therapy for patients with mycosis fungoides at different stages of the disease: a seven-year retrospective study in Russia. J Eur Acad Dermatol Venereol. 2019; 33:e72–e74.
Article
18. van Doorn R, Van Haselen CW, van Voorst Vader PC, Geerts ML, Heule F, de Rie M, et al. Mycosis fungoides: disease evolution and prognosis of 309 Dutch patients. Arch Dermatol. 2000; 136:504–510.
19. Lee HS, Suh KS, Lee DY, Cho KH, Oh SH, Kim SC, et al. Cutaneous lymphoma in Korea: a nationwide retrospective study. Acta Derm Venereol. 2016; 96:535–539.
Article
20. Park JH, Shin HT, Lee DY, Lee JH, Yang JM, Jang KT, et al. World Health Organization-European Organization for Research and Treatment of Cancer classification of cutaneous lymphoma in Korea: a retrospective study at a single tertiary institution. J Am Acad Dermatol. 2012; 67:1200–1209.
Article
21. Abeldaño A, Enz P, Maskin M, Cervini AB, Torres N, Acosta AC, et al. Primary cutaneous lymphoma in Argentina: a report of a nationwide study of 416 patients. Int J Dermatol. 2019; 58:449–455.
Article
22. van Santen S, van Doorn R, Neelis KJ, Daniëls LA, Horváth B, Bruijn MS, et al. Recommendations for treatment in folliculotropic mycosis fungoides: report of the Dutch Cutaneous Lymphoma Group. Br J Dermatol. 2017; 177:223–228.
Article
23. Kempf W, Ostheeren-Michaelis S, Paulli M, Lucioni M, Wechsler J, Audring H, et al. Cutaneous Lymphoma Histopathology Task Force Group of the European Organization for Research and Treatment of Cancer. Granulomatous mycosis fungoides and granulomatous slack skin: a multicenter study of the Cutaneous Lymphoma Histopathology Task Force Group of the European Organization For Research and Treatment of Cancer (EORTC). Arch Dermatol. 2008; 144:1609–1617.
Article
24. Amorim GM, Niemeyer-Corbellini JP, Quintella DC, Cuzzi T, Ramos-E-Silva M. Hypopigmented mycosis fungoides: a 20-case retrospective series. Int J Dermatol. 2018; 57:306–312.
Article
25. Ardigó M, Borroni G, Muscardin L, Kerl H, Cerroni L. Hypopigmented mycosis fungoides in Caucasian patients: a clinicopathologic study of 7 cases. J Am Acad Dermatol. 2003; 49:264–270.
Article
26. Boulos S, Vaid R, Aladily TN, Ivan DS, Talpur R, Duvic M. Clinical presentation, immunopathology, and treatment of juvenile-onset mycosis fungoides: a case series of 34 patients. J Am Acad Dermatol. 2014; 71:1117–1126.
Article